Kineta to Present at Biotech Showcase Investor Conference during JP Morgan Week in San Francisco

Advances in Chronic Pain Program to be Highlighted

Seattle, WA, January 6, 2017 – Kineta, Inc., a biotechnology company focused on the translational development of novel immune modulating therapies, today announced the company has been invited to present at the 9th Annual Biotech Showcase Investor Conference. Kineta CEO Dr. Shawn Iadonato will provide an overview of the company and KCP-400, a novel non-opioid in preclinical development for the treatment of chronic pain.

Dr. Iadonato will outline the robust analgesic, anti-inflammatory and neuroprotective effects that have been demonstrated in multiple pain models with this first in class therapeutic on Tuesday January 10th at 11:45AM. The Biotech Showcase Investor Conference will be held on January 9-11, 2017 at the Hilton San Francisco Union Square.

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in chronic pain, immuno-oncology and infectious diseases. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website,

KCP-400 is a first in class α9α10 nAChR antagonist with a novel mechanism of action. It is a highly potent synthetic peptide that is derived from the venom of a cone snail. KCP-400 is a non-opioid that has demonstrated robust analgesic, anti-inflammatory and neuroprotective effects across multiple preclinical chronic pain models. It was well tolerated with no observed toxicities in short-term studies.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.